-transparent.png){kind=logo}
Netilmicin, a new semisynthetic aminoglycoside, was evaluated in the therapy of 33 episodes of infection in 30 patients. Eighteen patients had documented bacteremia. Infection sites included pulmonary, urinary tract and soft tissue areas. A complete bacteriologic and clinical cure rate of 85 per cent was achieved. No treatment failures occurred in the bacteremic group. Although netilmicin is less effective than gentamicin in vitro against Pseudomonas, it was clinically and bacteriologically effective. Netilmicin bacteriologic cures occurred in patients whose organisms were inhibited by 6.2 microgram/ml or less of netilmicin. Despite a uniform dosing protocol, a wide range of netilmicin serum levels was obtained. Adverse effects were limited to one case of transient nephrotoxicity and one Candida urinary suprainfection. Netilmicin appears to be an effective, safe agent for the therapy of serious infections.
J A Jahre, and
K P Fu, and
H C Neu
November 1978,
The Journal of antimicrobial chemotherapy,
J A Jahre, and
K P Fu, and
H C Neu
January 1981,
Journal of the Oslo city hospitals,
J A Jahre, and
K P Fu, and
H C Neu
July 1989,
Journal of chemotherapy (Florence, Italy),
J A Jahre, and
K P Fu, and
H C Neu
October 1977,
Antimicrobial agents and chemotherapy,
J A Jahre, and
K P Fu, and
H C Neu
January 1978,
The Journal of international medical research,
J A Jahre, and
K P Fu, and
H C Neu
January 1981,
The Journal of international medical research,
J A Jahre, and
K P Fu, and
H C Neu
April 1995,
Clinical otolaryngology and allied sciences,
J A Jahre, and
K P Fu, and
H C Neu
January 1983,
Clinical therapeutics,
J A Jahre, and
K P Fu, and
H C Neu
January 1980,
Scandinavian journal of infectious diseases. Supplementum,
J A Jahre, and
K P Fu, and
H C Neu
April 1994,
The Journal of antimicrobial chemotherapy,
